SOURCE: PURE Bioscience, Inc

PURE Bioscience, Inc

April 15, 2014 08:36 ET

Food Manufacturer and Processor Customers Expand Use of PURE's SDC-Based Hard Surface Disinfectant

Re-Orders Follow Pilot Adoption Phase

SAN DIEGO, CA--(Marketwired - Apr 15, 2014) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today provided an update on the progress of the commercial adoption of the Company's SDC-based PURE® Hard Surface disinfectant and sanitizer by food manufacturers and processors. PURE has shipped re-orders from several manufacturers and processors as an expansion of successful pilot adoption and operating protocol development of various pathogen and hygiene control points in their plants.


  • Food processing customers of PURE Hard Surface report that they intend to expand their commercial pilot adoption of PURE Hard Surface for broader use now that they have completed extensive in-plant testing to determine the product's effectiveness against problem areas (such as walls, floors, conveyor belts and spiral freezers) where elimination of micro-organisms is difficult. PURE® Multi-Purpose Cleaner has also demonstrated superior cleaning to the current cleaners, particularly in difficult to treat drains. PURE Hard Surface, along with PURE Multi-Purpose cleaner, provides manufacturers and processors with new tools to treat areas where current products are not fully effective to combat potential food contamination risks.

  • Food processor customers have also experienced valuable labor saving advantages from the antimicrobial benefits of the product due to its 24-hour residual kill feature. Reduced production down time means increased plant productivity for these customers.

"As expected, PURE Hard Surface disinfectant and sanitizer is performing very well throughout all areas of the manufacturing facility. Additionally, customers have experienced enhanced elimination of persistent microorganisms in areas treated with our products," said Cliff Wechsler, PURE's Executive Vice President of Sales. "While the dollar value of these orders for product used as part of commercial pilot adoption is modest, the orders are meaningful as they represent validation of the SDC technology as an important food safety solution," Wechsler added.


  • As a result of close collaboration with its food manufacturing and processing customers, PURE is broadening its product portfolio. In the last 30 days the Company has developed PURE® Multi-Purpose High-Foam Cleaner for in-plant use offering its customers the additional option for their cleaning requirements.
  • PURE has also partnered with a leading equipment manufacturer to offer its customers spray and foaming units that are easily portable throughout the facility.

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control within the food industry. The Company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection. As a platform technology, SDC is distinguished from existing products in the marketplace by its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, including to manufacture its products, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact Information

  • IR Contacts:
    Tom Hemingway
    Redwood Investment Group
    Email Contact

    Terri MacInnis
    Director of IR
    Bibicoff + MacInnis, Inc.
    Email Contact

    Company Contact:
    Peter C. Wulff
    CFO & COO
    PURE Bioscience, Inc.
    Email Contact
    619-596-8600 ext.111